论文部分内容阅读
目的探讨Aur-A和表皮生长因子受体(EGFR)在肺腺癌组织中的表达及其与临床病理特征的关系。方法用免疫组化方法检测105例肺腺癌组织中Aur-A与EGFR的表达,并与临床病理因素进行相关性分析。结果 Aur-A在肺腺癌组织中的阳性率为71.4%(75/105)。Aur-A与EGFR表达呈正相关(r=0.416,P<0.05),Aur-A的表达与临床分期、淋巴结转移相关(P<0.05),Aur-A与EGFR的共表达与淋巴结转移有关(P<0.05)。结论 Aur-A阳性表达可作为评价肺腺癌发生发展的生物学指标,联合EGFR检测更有助于肺腺癌侵袭转移的判断。
Objective To investigate the expression of Aur-A and epidermal growth factor receptor (EGFR) in lung adenocarcinoma and its relationship with clinicopathological features. Methods The expressions of Aur-A and EGFR in 105 cases of lung adenocarcinoma were detected by immunohistochemistry, and their correlations with clinical pathological factors were analyzed. Results The positive rate of Aur-A in lung adenocarcinoma was 71.4% (75/105). The expression of Aur-A was positively correlated with EGFR (r = 0.416, P <0.05). The expression of Aur-A was correlated with clinical stage and lymph node metastasis (P <0.05) <0.05). Conclusion The positive expression of Aur-A may be used as a biological index to evaluate the occurrence and development of lung adenocarcinoma. Combined with EGFR detection, it is more helpful to judge the invasion and metastasis of lung adenocarcinoma.